Effects of lipid-lowering agents on diabetic retinopathy: a Meta-analysis and systematic review

作     者：Rui Shi Lei Zhao Feng Wang Fen Liu Zhuo Chen Rong Li Yang Liu Rong Lin 

作者机构：Department of Ophthalmology Shaanxi Provincial People's Hospital Department of Molecular Physiology and Biophysics Holden Comprehensive Cancer Center University of Iowa Carver College of Medicine Department of Ophthalmology the Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital) Department of Epidemiology and Health Statistics School of Public Health Capital Medical University School of Pharmacy Xi'an Medical University Department of Ophthalmology the First Affiliated Hospital Xi'an Medical University Central Laboratory Shaanxi Provincial People's Hospital Department of Pharmacology School of Basic Medical Sciences Xi'an Jiaotong University Health Science Center 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2018年第11卷第2期

页      面：287-295页

核心收录：

学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

基　　金：Supported by the National Natural Science Foundation of China(No.81500726) Science&Technology project for Social development of Shaanxi Province in China(No.2017SF-249) 

主　　题：DR DME Effects of lipid lowering agents on diabetic retinopathy:a Meta analysis and systematic review 

摘      要：AIM：To clarify this controversy and to provide evidence for application of lipid lowering agents in treatment of diabetic retinopathy（DR）.METHODS：We searched the databases of Pub Med,Embase and Cochrane Library Central Register of Controlled Trials（CENTRAL）and abstracts from main annual meetings up to January 1,*** scholar and Clinical *** were also searched for unpublished relevant *** included randomized controlled trials（RCTs）that studied lipid-lowering agents in type 1 or type 2 diabetes in this *** primary endpoint was the progression of DR,and the secondary endpoints included vision loss,development of diabetic macular edema（DME）and aggravation of hard *** pooled odds ratios（OR）with corresponding 95%confidence intervals（95%CIs）were ***：After systemic and manual literature search by two independent investigators,we included 8 RCTs from 7 published articles with 13 454 participants in this *** results revealed that lipid-lowering drugs were associated with reduced risk in DR progression[OR=0.77（95%CI：0.62,0.96）,P=0.02].Lipid-lowering agents might have protective effect on DME compared to placebo,although the difference was not statistically significant[OR=0.60（95%CI：0.34,1.08）,P=0.09].However,no significant differences in the worsening of vision acuity[OR=0.96（95%CI：0.81,1.14）,P=0.64]and hard exudates[OR=0.50（95%CI：0.15,1.74）,P=0.28]were found between the lipidlowering drugs and the placebo ***：In DR patients,lipid-lowering agents show a protective effect on DR progression and might be associated with reduced risk in the development of ***,lipid-lowering agents have no effects on vision loss and hard exudates *** clinical trials in larger scale are required to confirm the conclusion of this study and thus justify the use of intensive control lipids with anti-lipid agents at the early stages of DR.